StockGlow

Xvivo Perfusion AB (publ) (XVIVO.ST)

Builds machines that keep donor organs alive outside the body until transplant

251.40+0.00%Healthcare
Compare XVIVO.ST with
StockGlow Score
79
Leaning Bullish
BearishBullish
1 year ago+27.4%

The outlook

Xvivo Perfusion trades at 251.4 with strong analyst backing—the consensus leans "Strong Buy" with an average price target about 33% above current levels. The stock sits in the upper half of its 52-week range, though its price trend relative to moving averages is mixed. A high trailing P/E of 89.8 reflects elevated valuation relative to current earnings.

What’s behind the score

Analyst consensusStrong Buy — 1.3 avg of 5 analysts
Price trendMixed vs its moving averages
52-week range61% of the way from its 52-week low to high
Price targetAvg target +33% vs current price

Analyst price target

~12-month · 5 analysts
335.60average target+33.5% vs now
Now 251.40
Low 300.00High 385.00

Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.

Market cap
$7.92B
52-wk high
310.40
52-wk low
160.00
50-day avg
266.19
200-day avg
222.26
Trailing P/E
89.8

Similar stocks

BONEX.STBonesupport Holding AB (publ)$219.20+2.05%VITR.STVitrolife AB (publ)$85.95-0.64%CAMX.STCamurus AB (publ)$624.50+0.16%BIOA-B.STBioArctic AB (publ)$327.60+1.55%CEVI.STCellaVision AB (publ)$146.00+1.11%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy